Actuate Therapeutics shares surge 11.42% after-hours on positive follow-up data from Phase 2 trial.

Actuate Therapeutics surged 11.42% in after-hours trading following the release of positive follow-up data from its randomized controlled Phase 2 trial. The results demonstrated extended long-term overall outcomes, reinforcing the company’s therapeutic pipeline and investor confidence in its clinical-stage biotechnology platform. This development directly aligns with the stock’s upward movement, as the data strengthens the perceived value of Actuate’s ongoing research and potential future commercialization prospects.